Veru Inc ( (VERU) ) has released its Q1 earnings. Here is a breakdown of the information Veru Inc presented to its investors.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Veru Inc. is a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases. In its fiscal 2025 first quarter earnings report, Veru Inc. announced significant progress in its clinical programs, including positive results from the Phase 2b QUALITY study for enobosarm combined with semaglutide, as well as the sale of its FC2 Female Condom business for $18 million.
The company reported positive topline results from the Phase 2b QUALITY study, which demonstrated significant preservation of lean mass and greater fat loss in older patients receiving semaglutide. The study’s primary endpoint was met, showing a 71% relative reduction in lean mass loss and improved physical function. Additionally, Veru announced a new cardiometabolic indication for its drug sabizabulin to treat inflammation in atherosclerotic coronary artery disease.
Financially, Veru Inc. reported a decrease in net loss from continuing operations to $1.8 million, or $0.01 per share, compared to $7.7 million, or $0.08 per share, in the prior year. However, the overall net loss increased to $8.9 million, or $0.06 per share. The company’s research and development expenses rose significantly, reflecting its commitment to advancing its clinical programs.
Looking ahead, Veru Inc. plans to continue the QUALITY extension study with expectations to release topline results in the second quarter of 2025. Additionally, the company is preparing for a potential Phase 3 study of enobosarm and exploring further development of sabizabulin for treating atherosclerotic cardiovascular disease. These initiatives highlight Veru’s strategic focus on addressing unmet medical needs in cardiometabolic and inflammatory diseases.
